FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.
The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.
FibroBiologics is offering 1,028,788 shares of common stock, 1,243,940 pre-funded warrants and accompanying warrants to purchase up to 2,272,728 shares, at a combined public offering price of $1.32 per share plus warrant. Each public Warrant has an exercise price of $1.32 and is exercisable only after the effective date of the Warrant Stockholder Approval. Pre-Funded Warrants are exercisable for $0.00001 per share and are issued to limit single‑holder ownership above 4.99% (or electively 9.99%). The offering contemplates Placement Agent compensation including 159,091 Placement Agent Warrants and assumes delivery in a single closing. The prospectus gives effect to a 1-for-20 reverse stock split effective March 30, 2026, and states estimated net proceeds of approximately $2.5 million assuming full cash exercise of the Pre-Funded Warrants. The company remains listed on Nasdaq under FBLG and is taking these actions while seeking to regain compliance with Nasdaq bid-price requirements.
FibroBiologics, Inc. is registering up to 1,136,363 shares of common stock, up to 1,136,363 pre-funded warrants and related warrants in a best efforts public offering. Each share or pre-funded warrant is sold with a warrant, at an assumed combined price of $4.40. The company estimates net proceeds of about $4.3 million, intended for working capital and general corporate purposes. A 1-for-20 reverse stock split effective March 30, 2026 will reduce outstanding common shares from 70,256,883 to approximately 3,512,845, mainly to help regain Nasdaq bid-price compliance. The offering has no minimum size, may close with reduced proceeds and will cause immediate dilution for new investors.
FibroBiologics, Inc. filed Amendment No. 1 to its 2025 annual report to add the previously omitted Part III sections on directors, executive officers, compensation, security ownership, related‑party transactions and auditor fees. The company states the amendment does not change any prior financial results or other disclosures in the original 2025 report.
FibroBiologics, Inc. updated the compensation of its Chief Financial Officer. On March 4, 2026, the board’s Compensation Committee approved a new annual base salary of $400,000 for CFO Jason D. Davis, effective January 1, 2026. His target for annual non‑equity incentive compensation remains at 40% of base salary.
FibroBiologics, Inc. Chief Scientific Officer Hamid Khoja reported an open-market purchase of 30,000 shares of common stock at $0.3800 per share. Following this transaction, he directly owns 61,250 common shares.
FibroBiologics, Inc. chief executive officer Pete O'Heeron reported open-market purchases of 51,500 shares of common stock across three days. He bought 17,428 shares on March 2, 18,200 on March 3, and 15,872 on March 4, 2026, bringing his direct holdings to 5,958,147 shares.
FibroBiologics, Inc. Chief Financial Officer Jason Davis purchased 70,000 shares of the company’s common stock in an open-market transaction on March 2, 2026. The weighted average purchase price was $0.4139 per share, with individual trade prices ranging from $0.3968 to $0.4200. Following this transaction, Davis directly owns 70,000 common shares.
FibroBiologics, Inc. General Counsel Ruben A. Garcia bought 40,000 shares of common stock in an open-market purchase on February 27, 2026 at a weighted average price of $0.3264 per share. After this transaction, he directly owns 180,000 shares. The filing notes individual trade prices ranged from $0.3221 to $0.3268.
FibroBiologics, Inc. is a clinical-stage biotech company developing fibroblast-based cell therapies for chronic diseases such as wound healing, multiple sclerosis, degenerative disc disease, psoriasis, and longevity-related indications. Its approach uses allogeneic fibroblast single cells and spheroids as a scalable alternative to mesenchymal stem cells.
Lead program CYWC628 targets diabetic foot ulcers, with IND-enabling studies completed and a twelve-week Phase 1/2 trial in Australia planned for the first quarter of 2026. CYMS101 for multiple sclerosis has completed a five-patient Phase 1 safety study in Mexico, with a U.S. Phase 1/2 IND planned for the first half of 2026.
CybroCell™ for degenerative disc disease has supporting animal data and prior FDA IND clearance, while CYPS317 for psoriasis has an FDA Phase 1/2 IND filed on December 30, 2025. Early research programs include CYTER915 for thymus and spleen regeneration, a cancer initiative (TCB190), and an artificial pancreatic organoid program.
FibroBiologics, Inc. held a Special Meeting of Stockholders where all proposals were approved, including a key change to its capital structure. Stockholders authorized the Board to implement a reverse stock split of common and preferred stock at a ratio between 1-for-5 and 1-for-30 at the Board’s discretion within one year of approval. They also approved several proposals under Nasdaq Listing Rule 5635(d) allowing issuance of shares upon exercise of outstanding common warrants tied to prior securities purchase agreements and an engagement letter with H.C. Wainwright & Co., LLC. Attendance represented 54,974,113 votes out of 99,019,722 entitled to vote as of the record date.